We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
1151
Allogene Therapeutics
ALLO
$573M
$6K ﹤0.01%
416
-71
-15% -$1.25K
CDXS icon
1152
Codexis
CDXS
$159M
$6K ﹤0.01%
189
-32
-14% -$1.05K
ERAS icon
1153
Erasca
ERAS
$6.12B
$6K ﹤0.01%
+354
New +$6.06K
IRWD icon
1154
Ironwood Pharmaceuticals
IRWD
$604M
$6K ﹤0.01%
478
-80
-14% -$982
ITOS
1155
DELISTED
iTeos Therapeutics
ITOS
$6K ﹤0.01%
121
– –
PTGX icon
1156
Protagonist Therapeutics
PTGX
$8.74B
$6K ﹤0.01%
163
– –
TIL icon
1157
Instil Bio
TIL
$49.2M
$6K ﹤0.01%
+19
New +$7.33K
TVTX icon
1158
Travere Therapeutics
TVTX
$5.13B
$6K ﹤0.01%
208
– –
ISEE
1159
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6K ﹤0.01%
356
– –
GBT
1160
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6K ﹤0.01%
214
– –
AGIO icon
1161
Agios Pharmaceuticals
AGIO
$2.09B
$5K ﹤0.01%
158
-44
-22% -$1.77K
AMRN
1162
Amarin Corp
AMRN
$299M
$5K ﹤0.01%
67
– –
ATRA icon
1163
Atara Biotherapeutics
ATRA
$69.7M
$5K ﹤0.01%
12
– –
AXSM icon
1164
Axsome Therapeutics
AXSM
$11.8B
$5K ﹤0.01%
129
– –
CCCC icon
1165
C4 Therapeutics
CCCC
$387M
$5K ﹤0.01%
+142
New +$5.62K
EDIT icon
1166
Editas Medicine
EDIT
$391M
$5K ﹤0.01%
200
-34
-15% -$1.17K
ENTA icon
1167
Enanta Pharmaceuticals
ENTA
$364M
$5K ﹤0.01%
69
– –
GMAB icon
1168
Genmab
GMAB
$17.5B
$5K ﹤0.01%
137
-28
-17% -$1.17K
KROS icon
1169
Keros Therapeutics
KROS
$197M
$5K ﹤0.01%
80
– –
KRYS icon
1170
Krystal Biotech
KRYS
$10.6B
$5K ﹤0.01%
76
– –
LYEL icon
1171
Lyell Immunopharma
LYEL
$317M
$5K ﹤0.01%
+35
New +$7.81K
MDGL icon
1172
Madrigal Pharmaceuticals
MDGL
$12.5B
$5K ﹤0.01%
57
– –
RCKT icon
1173
Rocket Pharmaceuticals
RCKT
$333M
$5K ﹤0.01%
218
– –
RGNX icon
1174
Regenxbio
RGNX
$616M
$5K ﹤0.01%
146
– –
RVMD icon
1175
Revolution Medicines
RVMD
$38.3B
$5K ﹤0.01%
215
-37
-15% -$1.04K
45 46
47
48 49

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.